Elicio Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Elicio Therapeutics, Inc. (ELTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$39.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-12
- Elicio Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$39.48M.
- Elicio Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$51.73M.
- Elicio Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$38.30M.
- Elicio Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$53.55M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$39.48M 10-K · filed 2026-03-12 |
| 2024-12-31 | -$51.73M 10-K · filed 2026-03-12 |
| 2022-12-31 | -$38.30M 10-K · filed 2023-03-17 |
| 2021-12-31 | -$53.55M 10-K · filed 2023-03-17 |
| 2020-12-31 | -$78.16M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |